ERBB2 and breast carcinoma: In its current use, fulvestrant is approved in postmenopausal HR+HER2- metastatic breast cancer following progression on previous endocrine treatment at a dose of 500 mg every 4 weeks, after an initial month of biweekly loading dose [15–16].